Donepezil Double Blind Trial for ECT Memory Disfunction

BeerYaakov Mental Health Center

Status and phase: Unknown; Phase 4

Conditions: Schizophreniform Disorder; Schizophrenia; Schizoaffective Disorder

Treatments: Drug: Donepezil

Study type: Interventional

Funder types: Other

Identifiers

NCT00465283

Donepezil-180CTIL

Details and patient eligibility

About

This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT.

Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Schizophrenia, Schizoaffective disorder, schizophreniform disorder patients who meet criteria for diagnoses by DSM-IV criteria and evaluated by the Structured Clinical Interview for DSM-IV (SCID)

Exclusion criteria

• History of serious neurological disorders including neurodegenerative deseases, mental retardation, substance and/or alcohol dependence.
• Pregnant women
• Patients who recieved ECT within 6 month
• Patients whith contraindication to Donepezil treatment.
• Patients with Lithium treatment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

40 participants in 2 patient groups, including a placebo group

Donepezil

Active Comparator group

Treatment:

Drug: Donepezil

placebo

Placebo Comparator group

Treatment:

Drug: Donepezil